… study was to determine the value of emicizumab for the prophylaxis of haemophilia A with
inhibitors … Two structured evidence matrices were developed: emicizumab against activated …

… study was to determine the value of emicizumab for the prophylaxis of haemophilia A patients
… study where was determined the value of emicizumab for the prophylaxis of HA patients …

… ±2.1 emicizumab/Feiba® and -0.3±0.7 emicizumab/Novoseven®… System capacity and
appropriate use of emicizumab were … CONCLUSIONS: Emicizumab adds higher therapeutic value …

… of emicizumab determine its role in the management of haemophilia. Hemlibra® perfectly …
Eligibility criteria for long-term bleeding prophylaxis with emicizumab are set forth in the …

… emicizumab as a treatment of choice that should be considered in all patients with severe
hemophilia A rather than a ‘salvage therapy’ for patients not currently on prophylaxis (due to …

… Emicizumab has contributed in a major way to this revolution as the first of the non-clotting …
the development of emicizumab, the drug’s initial success for prophylaxis against bleeds …

… emicizumab (Hemlibra ® ). This study aims to investigate patient-centred access to treatment
… low waiting time also contribute to better access to emicizumab in community pharmacies. …

… Emicizumab (Hemlibra™) is approved for prophylaxis of Haemophilia A (HA) patients with
… All authors have made substantial contributions to the conception or design of the work, …

… clinical and economic value of this … prophylaxis therapy with emicizumab) in high titer
inhibitory HA patients. The aim of this study was to evaluate the cost-utility of emicizumab (Hemlibra…

… 1 trial, weekly emicizumab (Hemlibra®) prophylaxis injection reduces … contribute to assessing
the value of emicizumab prophylaxis and help determine whether emicizumab prophylaxis …